Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines

Research output: Contribution to journalArticleAcademic

23 Citations (Scopus)
Original languageEnglish
JournalValue in Health
DOIs
Publication statusPublished - 31 Jul 2017

Cite this